Abstract
Introduction While Parkinson’s disease (PD) related neurodegeneration is associated with structural changes in the brain, magnetic resonance imaging (MRI) has not been helpful in diagnosing PD or predicting the progression of motor symptoms. In this study, we aimed to develop a structural MRI-based biomarker to predict the rate of progression of motor symptoms and to classify patients based on the symptom severity (i.e. slow vs. fast progressors) in the early stages of PD.
Methods The study included 59 patients with PD (n=40 for the primary analysis, 19 for the validation analysis), and 55 healthy controls with structural MRI from the Parkinson’s Progression Markers Initiative (PPMI) database. We developed a patient-specific multivariate gray matter volumetric distance using Mahalanobis distance (MGMV) to investigate the changes in MGMV over time using longitudinal linear mixed-effect model, its potential as a biomarker to predict the rate of progression of motor function (MDS-UPDRS-part III) using multiple linear regression model, and classification of patients based on symptom severity using machine learning (ML).
Results MGMV at BL significantly predicted changes in motor severity (p<0.05) and a trend level increase in MGMV over time (p = 0.09) were noted. We obtained 85% accuracy in discriminating patients according to their symptom severity, and on an independent test cohort, an accuracy of 90% was achieved.
Conclusions We identified a promising structural MRI-based biomarker for predicting the rate of progression of motor symptoms and classification of patients based on motor symptom severity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data used in this study was downloaded from the Parkinsons Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data) through a standard application process. For up-to-date information on the study, please visit www.ppmi-info.org.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data used in this study was downloaded from the Parkinsons Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data) through a standard application process. For up-to-date information on the study, please visit www.ppmi-info.org.